In vivo antimalarial evaluation of some 2,3-disubstituted-4(3H)-quinazolinone derivatives
- 865 Downloads
Malaria is a neglected tropical parasitic disease affecting billons of people around the globe. Though the number of cases and deaths associated with malaria are decreasing in recent years, it is the most deadly disease in the world. This study aimed at investigating the in vivo antimalarial activities of some 2,3-disubstituted-4(3H)-quinazolinone derivatives.
The in vivo antimalarial activities of the test compounds (6–9 and 11–13) were investigated using the 4-day suppressive standard test in mice infected with chloroquine-sensitive Plasmodium berghei ANKA strain. The tested compounds showed significant antimalarial activities with mean percentage suppression of 43.71–72.86 % which is significantly higher than the negative control group (p < 0.05). Compounds 12 and 13 displayed better antimalarial activities from the group with mean percentage suppression of 67.60 and 72.86 % respectively.
The tested compounds showed significant in vivo antimalarial activities in mice infected with P. berghi ANKA strain. Thus, 3-aryl-2-(substitutedstyryl)-4(3H)-quinazolinones represent a possible scaffold for the development of antimalarial agents.
artemisinins combination therapy
red blood cells
Addis Ababa University
Ethiopian Pharmaceuticals manufacturer
Malaria is a neglected tropical parasitic disease caused by a Plasmodian protozoan species . It is transmitted by the bite of female Anopheles mosquito through injection of sporozoites at the time of blood suck . In 2012, there were an estimated 3.4 billion people at risk of malaria, of whom 1.2 billion are at high risk. Children, pregnant women, HIV patients and travelers to sub-Saharan African countries are at increased risk of severe malaria, if infected with P. falciparum . The global number of malaria cases and deaths were estimated to have decreased since 2005 due to the expansion of access to rapid diagnostic tests, use of long-lasting insecticidal nets (136 million in 2013), quality assured artemisinin combination therapy (ACT) (331 million courses were produced in 2012) and increased funding for malaria control programs (US$ 2.5 billion in 2012) [4, 5].
Artemisinins and ACT with fixed dose combinations are the first-line treatment for falciparum malaria in almost all regions where malaria is endemic [6, 7] due to the emergence of resistance P. falciparum strains to the older drugs [8, 9, 10]. Although artemisinins are potent and rapidly acting antimalarial drugs, their widespread use for treating patients with P. falciparum malaria raises the question of emerging drug resistance . Research findings revealed that treatment failures to artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (ALU) has been observed in different parts of the globe [12, 13]. In addition, artemisinin resistance has already emerged along the Thai-Cambodian border [14, 15]. Taking this into account, an aggressive and ambitious global effort is being made to discover new effective drugs for the treatment of malaria [16, 17].
The quinazoline nucleus, a basic unit found in various naturally occurring bioactive alkaloids, have continued to attract interest due to their diverse pharmacological activities [18, 19, 20, 21]. Different reports revealed that a wide number of quinazolinone derivatives demonstrated promising antimalarial activities [20, 22]. Recently, our group has synthesized and tested the antileishmanial activities of some 2,3-disubstituted-4(3H)-quinazolinone derivatives . The aim of the present study was to evaluate the in vivo antimalarial activities of these compounds (6–9 and 11–13) using Swiss albino mice infected with chloroquine-sensitive P. berghei ANKA strain. In addition, oral acute toxicity tests were performed for compounds with significant antimalarial activities.
Chemicals and reagents
Absolute ethanol, absolute methanol, distilled water, iodine, Giemsa stain, Tween 80, 1 % gum acacia were used in the study.
Experimental animals and test strains
Swiss albino male mice (age 6–8 weeks and weight 20–32 g) bred and maintained under standard conditions (temperature of 22 ± 3 °C, relative humidity of 40–50 % and 12 h light/12 h dark cycle), with food and water ad libitum in the animal house of Biomedical Laboratory, Department of Biology, Faculty of Sciences, Addis Ababa University (AAU). They were acclimatized for one week for the experimental conditions.
Chloroquine-sensitive P. berghei ANKA strain used to infect the mice for a 4-day suppressive test was obtained from Biomedical Laboratory, Department of Biology, Faculty of Sciences, AAU. The parasite was maintained by serial passage of blood from infected mice to non-infected ones on weekly basis.
For the in vivo antimalarial activity testing, chloroquine phosphate (EPHARM, Addis Ababa, Ethiopia) was used as a reference drug.
In vivo antimalarial activity test
Swiss albino mice previously infected with P. berghei and having parasitemia level of 20–30 % were used as donors. The donor mice was then sacrificed by decapitation and blood was collected by cardiac puncture into heparinized vacutainer tube containing 0.5 % trisodium citrate. The blood was then diluted with physiological saline based on parasitemia level of the donor mice and the red blood cell (RBC) count of normal mice, in such a way that 1 ml of blood contains 5 × 107 infected RBCs. Each mouse was given 0.2 ml of diluted blood intrapreritoneally, which contained 1 × 107 P. berghei infected RBCs .
Both chloroquine phosphate and the test compounds (6–9 and 11–13) were dissolved in 70 % Tween 80 and 30 % ethanol. These solution were further diluted tenfold with distilled water to result in stock solutions containing 7 % Tween 80 and 3 % ethanol.
Grouping and dosing of animals
For the antimalarial evaluations of the target compounds, infected mice were randomly divided into nine groups of five mice per cage. Group 1 served as a negative control and group 2 served as a positive control. A vehicle containing a solution of 7 % Tween 80, 3 % ethanol and 90 % distilled water (2 ml/100 g) and chloroquine phosphate 25 mg/kg (48.46 µmol/kg) was administered orally to group 1 and 2 respectively. The remaining groups (group 3–9) were treated with equimolar amounts (48.46 µmol/kg) of the synthesized compounds through oral route for four consecutive days .
For the oral acute toxicity studies of each compound (12 and 13), 36 male Swiss albino mice (approximately 20 g each) were randomly assigned to six groups (containing six mice per group). Group 1–5 were treated with each compound suspended in a vehicle containing 1 % gum acacia at a dose of 10, 50, 100, 200 and 300 mg/kg, respectively. The sixth group received vehicle containing 1 % gum acacia (served as a negative control group) at a maximum dose of 1 ml/100 g of body weight by oral route .
The standard 4-day suppressive test
The 4-day standard suppressive test was used to evaluate the in vivo antimalarial activities of the test compounds using P. berghei infected mice . Infected mice were randomly divided into their respective group as described under grouping and dosing. Treatment was started 2 h after mice had been inoculated with the parasite and continued for four consecutive days. Twenty-four hours after the last treatment (5th day), blood smears were taken from the tail of all mice, air dried, fixed with absolute methanol and stained with 6 % Giemsa stain. The parasitemia and percentage inhibition were then determined microscopically by counting four fields of approximately 100 erythrocytes per field. The efficacies of compounds were finally assessed by comparison of blood parasitemia and mouse survival time in treated and untreated control mice .
In vivo acute toxicity test
The oral acute toxicities of the test compounds (12 and 13) with promising antimalarial activities were investigated in a dose of 10, 50, 100, 200 and 300 mg/kg. Animals were observed for gross body changes such as loss of appetite, hair erection, lacrimation, convulsions, salivation, diarrhea, mortality and other signs of overt toxicity .
The care and handling of the experimental animals was according to international guideline for use and maintenance of experimental animals  and Addis Ababa University, School of Pharmacy Ethics committee approved the protocol.
Results of the study were expressed as mean ± standard deviation and statistical significance for suppressive test was determined by one-way ANOVA using Origin 6.0 software. Data on survival time, percentage parasitemia and percentage suppression was analyzed using Microsoft office excel 2007. All data was analyzed at 95 % confidence interval.
Results and discussion
In vivo antimalarial activity results
Data for antimalarial activity testing of the synthesized compounds (48.46 µmol/kg)
The percentage parasitemia determined for all test compounds were significantly low relative to the negative control (p < 0.05), showing that the compounds are active. This significant antimalarial activity of the target compounds was also in agreement with that of the activity of 4(3H)-quinazolinone derivatives on the same parasite strain . The test compounds, 6, 7, 11, 12, and 13 displayed mean percentage suppression of greater than 50 %. On the other hand, compounds 8 and 9 had less than 50 % mean percent suppression compared to the untreated group (Table 1).
Compound 13 was the most active of the tested compounds with mean percentage suppression of 72.86 %. The mean parasitemia level in mice treated with 13 (17.71 ± 0.45) was found to be approximately four times lower than the negative control (65.25 ± 0.73), showing the compound has greatly reduced the parasite load. This significant activity was further supported by better mean survival time (9.2 ± 0.43) of mice compared with other test compounds but less than those of positive control (chloroquine-treated) group that did not show any death during the experimental period. Compound 12 displayed the next significant (p < 0.05) antimalarial activity with percentage suppression of 67.60 % that is further confirmed by mean survival time (8.3 ± 0.55) (Table 1). The highest suppression effect of 12 and 13 may be attributed to the presence of polar groups [hydroxyl group (–OH) in both 12 and 13, methoxy group (–OCH3) in 13] at 2-styryl moiety that may interact through hydrogen bonding with the active site.
The remaining compounds; 6, 7 and 11 demonstrated moderate antimalarial activities with mean percentage suppression of 55.41, 56.34 and 53.58 % respectively. These compounds possess electron withdrawing group at para position of 2-styryl group, which may increase the likelihood of strong hydrophobic interaction between the compounds and the active sites. However, they displayed relatively lower antimalarial activities as compared to compound 12 and 13.
Acute toxicity results
The acute toxicity study indicated that compounds 12 and 13 caused no mortality in all doses (50, 100, 200 and 300 mg/kg) within the first 24 h as well as for the following 14 days. Physical and behavioral observations of the experimental mice also revealed no visible signs of overt toxicity. Thus, compound 12 and 13 showed no inherent acute toxicity signs at a maximum dose of 300 mg/kg.
The antimalarial activities of some 3-aryl-2-(substitutedstyryl)-4(3H)-quinazolinone derivatives were tested. All the tested compounds showed significant antimalarial activities as compared to the negative control group (p < 0.05). Better antimalarial activities were observed for compound 12 and 13 with mean percentage suppression of 72.86 and 67.60 % respectively. Thus, 2,3-disubstituted-4(3H)-quinazolinines containing an aromatic substitution at 3-position and substitutedstyryl moiety at 2-position represent a possible scaffold for the development of new antimalarial agents.
YSB conducted the actual study and the statistical analysis. YSB, AAB and AH were involved in developing the idea and designing of the study. YSB and AH were also involved in the write up of the manuscript. All authors read and approved the final manuscript.
Authors are thankful to Prof. Alemtsehay Mekonnen for permitting us to carry out the antimalarial activity test at the Biomedical Laboratory in the Department of Biology, Faculty of Science, AAU.
The authors declare that they have no competing interests.
- 4.WHO. The world malaria report from WHO global malaria program. Geneva: World Health Organization; 2010.Google Scholar
- 5.WHO. The world malaria report from WHO global malaria program. Geneva: World Health Organization; 2013.Google Scholar
- 6.Smithuis F, Kyaw MK, Phe O, Aye KH, Htet L, Barends M, Lindegardh N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White NJ. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomized comparison. Lancet. 2006;367:2075–85.CrossRefPubMedGoogle Scholar
- 11.Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, Incardona S, Lim P, Sem R, Socheat D, Chiristophel EM, Ringwald P. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006;11:1360–6.CrossRefPubMedGoogle Scholar
- 12.Hasugian AR, Purba HLE, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PMP, Laihad F, Anstey NM, Tjitra E, Price RN. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and post-treatment prophylaxis against multidrug-resistant P. falciparum and P. vivax malaria. Clin Infect Dis. 2007;44:1067–74.PubMedCentralCrossRefPubMedGoogle Scholar
- 13.Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother. 2006;50:1893–5.PubMedCentralCrossRefPubMedGoogle Scholar
- 14.Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungduen D, Nakavej A, Wongsrichanalai C. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate- mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health. 2006;11:211–9.CrossRefPubMedGoogle Scholar
- 17.Franklin BS, Ishizaka ST, Lamphier M, Gusovsky F, Hansen H, Rose J, Zheng W, Ataíde MA, de Oliveira RB, Golenbock DT, Gazzinelli RT. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc Natl Acad Sci USA. 2011;108:3689–94.PubMedCentralCrossRefPubMedGoogle Scholar
- 18.Shivananda MK, Holla BS. Antifungal activity studies of some quinazolinone derivatives. J Chem Pharm Res. 2011;3:83–6.Google Scholar
- 30.The Organization of Economic Co-operation and Development (OECD). The OECD guidelines for testing of chemicals 420, acute oral toxicity. France; 2001.Google Scholar
- 32.Dikasso D, Mekonnen E, Debella A, Abebe D, Urga K, Mekonnen W, Melaku D, Assefa A, Mekonnen Y. In vivo antimalarial activity of hydroalcoholic extracts from Asparagus africanus Lam. in mice infected with Plasmodium berghei. Ethiop J Health Dev. 2006;20:112–8.Google Scholar
- 33.Peter IT, Anatoli VK. The current global malaria situation Malaria parasite biology, pathogenesis and protection. Washington, DC: ASM press; 1998. p. 11–22.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.